Stauder, Reinhard
Yu, Ge http://orcid.org/0000-0002-0891-2501
Koinig, Karin A.
Bagguley, Tim
Fenaux, Pierre
Symeonidis, Argiris
Sanz, Guillermo http://orcid.org/0000-0002-2767-8191
Cermak, Jaroslav
Mittelman, Moshe
Hellström-Lindberg, Eva
Langemeijer, Saskia
Holm, Mette Skov
Mądry, Krzysztof
Malcovati, Luca
Tatic, Aurelia
Germing, Ulrich
Savic, Aleksandar
van Marrewijk, Corine
Guerci-Bresler, Agnès
Luño, Elisa
Droste, Jackie
Efficace, Fabio
Smith, Alex
Bowen, David
de Witte, Theo
Article History
Received: 21 December 2017
Revised: 25 January 2018
Accepted: 30 January 2018
First Online: 6 March 2018
Compliance with ethical standards
:
: This study was carried out within the EUMDS Registry which is supported by Novartis Oncology. T. de Witte is the project leader and C. van Marrewijk is the project manager of the EUMDS Registry. Outside the funding by Novartis Oncology, the following co-authors report grants or personal fees: R. Stauder received research funding and honoraria from Celgene, Teva and Novartis. T. de Witte reports grants from Celgene, personal fees from Incyte, personal fees from Amgen, personal fees from Incyte outside the submitted work. G. Sanz reports personal fees by Celgene. M. Mittelmann reports personal fees by Ofizer, Amgen, research grants by Celgene/Neopharm, and advisory roles for Celgene, Amgen, and Janssen. A. Savic personal fees by Seattle Genetics, Novo Nordisk, and Amgen. F. Efficace reports personal fees by Bristol-Myers Squibb, Seattle Genetics, TEVA and Incyte; and research funding by Lundbeck, TEVA, and Amgen. The remaining authors declare that they have no conflict of interest.